156 related articles for article (PubMed ID: 1593713)
1. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.
Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
J Urol; 1992 Jun; 147(6):1636-42. PubMed ID: 1593713
[TBL] [Abstract][Full Text] [Related]
2. HLA-DR expression by high grade superficial bladder cancer treated with BCG.
Prescott S; James K; Busuttil A; Hargreave TB; Chisholm GD; Smyth JF
Br J Urol; 1989 Mar; 63(3):264-9. PubMed ID: 2522806
[TBL] [Abstract][Full Text] [Related]
3. Local immune responses after intravesical BCG treatment for carcinoma in situ.
el-Demiry MI; Smith G; Ritchie AW; James K; Cumming JA; Hargreave TB; Chisholm GD
Br J Urol; 1987 Dec; 60(6):543-8. PubMed ID: 3501324
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
6. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
8. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall.
Böhle A; Gerdes J; Ulmer AJ; Hofstetter AG; Flad HD
J Urol; 1990 Jul; 144(1):53-8. PubMed ID: 2359181
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cellular tumour rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment.
Saint F; Patard JJ; Groux Muscatelli B; Lefrere Belda MA; Gil Diez de Medina S; Abbou CC; Chopin DK
BJU Int; 2001 Oct; 88(6):602-10. PubMed ID: 11678759
[TBL] [Abstract][Full Text] [Related]
10. Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cells.
Hermann GG; Petersen KR; Zeuthen J; Steven K
Scand J Urol Nephrol; 1991; 25(4):269-73. PubMed ID: 1780700
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.
Jurincic-Winkler C; Metz KA; Beuth J; Engelmann U; Klippel KF
Br J Urol; 1995 Dec; 76(6):702-7. PubMed ID: 8535712
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer.
Patard JJ; Muscatelli-Groux B; Saint F; Popov Z; Maille P; Abbou C; Chopin D
Br J Urol; 1996 Nov; 78(5):709-14. PubMed ID: 8976765
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
14. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
15. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
[TBL] [Abstract][Full Text] [Related]
18. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
19. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
20. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.
Prescott S; James K; Hargreave TB; Chisholm GD; Smyth JF
J Urol; 1990 Nov; 144(5):1248-51. PubMed ID: 2122008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
